UKMedix Logo
48hr 10% off offer from ukmedix
pharmacy check uk

Acomplia is no longer available at UKMedix

Acomplia (Sanofi) has been temporarily suspended with immediate effect, following advice from the European Medicines Agency and the MHRA because the benefits are thought to no longer outweigh the risks. The most recent studies showed that there was an increased risk of psychiatric disorders in patients taking Acomplia.

If you have already been taking Acomplia and wish to continue:

You should contact your doctor or pharmacist as soon as it is convenient to discuss your treatment.

If you were wishing to take Acomplia for the first time:

You should consider alternate weight loss treatments from UKMedix such as Xenical or Reductil.

Some of our recent news stories on acomplia
  • Acomplia In UK News - 31/05/2007

    The weight loss drug Acomplia has been in the UK news recently as it is being claimed by a Drug and Therapeutics Bulletin in the United Kingdom that while the Acomplia drug is effective for weight loss it is not properly proven that the medicine can have an ...

  • Acomplia Weight Loss Drug Copied In India - 28/05/2007

    The big French drug company Sanofi-Aventis has learnt that its new weight loss drug Acomplia is being copied in India by three different drug companies. According to recent reports Torrent Pharmaceutical, Sun Pharmaceuticals and Zydus Cadila have made generic versions of this new diet drug.  Acomplia has only ...

  • Sanofi Aventis Explains Why Acomplia Is Zimulti In US - 11/05/2007

    Up until very recently nobody knew why the weight loss drug Acomplia made by the pharmaceutical giant Sanofi Aventis was going to be named Zimulti in the United States of America. The name Acomplia was widely accepted in Europe and was fast gaining brand recognition as a weight ...

  • Acomplia Sales In EU Likely To Grow Slowly - 10/05/2007

    The financial figures released by the drug company Sanofi Aventis show that while sales of their weight loss drug Acomplia are significant at 15 million euros they have not attained the sort of levels that would justify the vast amount of investment in research and development that went ...

  • Sanofi Aventis Banking On Acomplia Approval - 09/05/2007

    Despite showing lower 1st quarter results the drug manufacturer Sanofi-Aventis has raised its final year profit forecast partly on the basis that the weight loss drug Acomplia should be OK'ed for sale in the United States of America. These are nervous times for Sanofi Aventis who have staked much ...